Mazdutide
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
Innovent · Phase 1 · Completed · Enrollment 36
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 362-dose1-4mg | n/r | n/r | n/r | n/r |
| 362-dose2-6mg | n/r | n/r | n/r | n/r |
| 362-dose3-Placebo | n/r | n/r | n/r | n/r |
Not shown
- 362-dose1-4mg: endpoint not reported
- 362-dose2-6mg: endpoint not reported
- 362-dose3-Placebo: endpoint not reported